Menu
Search
|

Menu

Close
X

Editas Medicine Inc EDIT.OQ (NASDAQ Stock Exchange Global Select Market)

25.92 USD
+0.17 (+0.66%)
As of 12:19 PM EDT
Previous Close 25.75
Open 25.78
Volume 45,078
3m Avg Volume 222,550
Today’s High 26.09
Today’s Low 25.54
52 Week High 33.79
52 Week Low 17.90
Shares Outstanding (mil) 41.74
Market Capitalization (mil) 1,043.82
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.30 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
4
FY18
32
FY17
14
FY16
6
EPS (USD)
FY19
-1.287
FY18
-2.341
FY17
-2.993
FY16
-3.031
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
185.11
7.91
Price to Book (MRQ)
vs sector
5.53
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
26.42
14.55
LT Debt to Equity (MRQ)
vs sector
18.31
10.20
Return on Investment (TTM)
vs sector
-42.42
14.48
Return on Equity (TTM)
vs sector
-63.35
15.78

EXECUTIVE LEADERSHIP

James Mullen
Independent Chairman of the Board, Since 2018
Salary: --
Bonus: --
Cynthia Collins
President, Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Eric Ek
Interim Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer, Since 2019
Salary: --
Bonus: --
Vickesh Myer
Chief Technology Officer, Since 2015
Salary: $363,377.00
Bonus: $123,549.00
Charles Albright
Chief Scientific Officer, Since 2016
Salary: $390,654.00
Bonus: $132,823.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11 Hurley St
CAMBRIDGE   MA   02141-2110

Phone: +1617.4019000

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

SPONSORED STORIES